5Vote!
Market Watch (Free subscription) | 3 hours ago
TEL AVIV (MarketWatch) -- Incyte Corp., the Wilmington, Del., drug developer focused on cancer, inflammation and diabetes, said it licensed two investigational hematology-oncology therapies to Novartis, the Basel health-care giant. The drugs are INCB18424, in Phase III development for myelofibrosis; and INCB28060, which is about to enter Phase I development as a potential treatment for multiple cancers....
4Vote!
Business Wire (Free subscription) | 4 hours ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone...
4Vote!
PR News Wire (Free subscription) | yesterday
SAN DIEGO, Nov. 24 /PRNewswire/ -- Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety...
3Vote!
Medical News Today (Free subscription) | yesterday
The American Society of Hematology (ASH) and Scholastic, the global children's publishing, education, and media company, are launching "Explore the Mystery of Blood," a dynamic science curriculum designed to spark interest in the fields of science and medicine, in addition to exposing students to exciting career opportunities in hematology.
4Vote!
Business Wire (Free subscription) | 11/23/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society...
3Vote!
Medical News Today (Free subscription) | 11/20/2009
For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder. Mendelian disorders, such as cystic fibrosis and sickle cell disease, are the result of one or more mutations in a single gene, typically a gene that makes a protein. All of the regions that code for proteins taken together are called...
5Vote!
Market Wire (Free subscription) | 11/19/2009
REDWOOD CITY, CA (MARKET WIRE) Facet Biotech Corporation (NASDAQ: FACT) today announced that data for the company's elotuzumab and TRU-016 development programs will be presented at the American Society of Hematology (ASH) 2009 Annual Meeting and Exposition taking place in New Orleans, La. at the Ernest N. Morial Convention Center, December 5 - 8, 2009.
4Vote!
Business Wire (Free subscription) | 11/16/2009
VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans. The results of these trials will be highlighted in two...
3Vote!
Medical News Today (Free subscription) | 11/15/2009
First reported interim data from the Evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment (ACCELERATE) trial were presented today at the Neurocritical Care Society (NCS) 2009 Annual Meeting, showing that Cleviprex (clevidipine butyrate) effectively and safely reduces blood pressure in patients with acute, non-traumatic intracerebral hemorrhage...
3Vote!
Medical News Today (Free subscription) | 11/14/2009
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
4Vote!
The Earth Times Online Newspaper (Free subscription) | 11/12/2009
SUNNYVALE, Calif., Nov. 12 -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orlea...
4Vote!
PR News Wire (Free subscription) | 11/11/2009
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The...
4Vote!
Business Wire (Free subscription) | 11/11/2009
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009. Four poster presentations will summarize...
5Vote!
Business Wire (Free subscription) | 11/11/2009
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID®, VIDAZA®, THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting...
5Vote!
aarkstore | 09/09/2009
Clinical hematology analyzer analysis is one of the oldest and most important sectors of clinical laboratory analysis. The hematology instrument and reagent market is centered around a group of instruments called hematology analyzers. The term clinical hematology analyzer usually refers to an automated instrument for determining the presence, number and type of cellular elements in easily collected...
Videos